Mithra Signs Exclusive Agreement for Tibelia® in Canada

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has signed an exclusive License and Supply Agreement for Tibelia®, its generic version of tibolone for use in Hormone Therapy (HT), with an undisclosed Canadian partner. Tibelia® is a generic version of Livial®.

There are currently no tibolone-based products on the market in Canada for the relief of postmenopausal symptoms and prevention of osteoporosis in post-menopausal women. Subject to obtaining marketing approval from Health Canada, Tibelia® would therefore be launched as a new treatment option for these indications in Canada. The dossier seeking marketing approval has already been submitted.

 

 

The Canadian menopausal health market is currently valued at approximately EUR 80 million1 , with further growth potential as new products are introduced, offering a promising opportunity for Tibelia®. Mithra intends to produce Tibelia® at its own research and production facility (Mithra CDMO2 ), so that this new agreement would not only generate milestone payments but also additional revenues through supply agreements.

 

François Fornieri, CEO of Mithra, commented: “The Canadian market represents an important opportunity for Tibelia® and has the potential to offer women in Canada new options to safely address menopausal symptoms. This agreement follows the completion of the decentralized approval procedure for Tibelia® in Europe and demonstrates the increasing momentum and interest in Tibelia® in a growing number of markets. We look forward to establishing further partnerships for both our potentially game-changing E4-based pipeline, with Estelle® for contraception and Donesta® for menopause, and our Complex Therapeutics, such as Myring™ and Tibelia®.”

Note

About Tibelia®
Tibelia® is a synthetic steroid (tibolone) intended to be used for Hormone Therapy (HT). Tibelia® is a bioequivalent of Livial® 2.5mg which is a product that mimics the activity of the female sex hormones in the body, and is used especially for the relief of symptoms occurring after menopause. This includes the relief of postmenopausal symptoms, in addition to prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products. It has been demonstrated that tibolone has favorable effects on various tissues in the body, such as brain, vagina and bone.3

About Mithra
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women’s health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

 

 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?